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1. Introduction 
The high costs incurred when drugs fail during clinical trials has prompted interest in 
biomarkers as biological indicators for progress of disease, effect of therapeutic 
interventions, and/or drug-induced toxicity. One of the goals is to reduce attrition of drugs 
during the clinical, and probably preclinical, phases of drug development, and hence, the 
overall cost of drug development.  
The role of biomarkers has been exponentially increasing in guiding decisions in every 
phase of drug development, from drug discovery and preclinical evaluations through each 
phase of clinical trials and into post-marketing studies. In early phases of drug 
development, biomarkers are used to evaluate activity in animal models, prove mechanism 
of action and concept of an investigational entity, bridge pre-clinical and clinical 
pharmacology, and evaluate safety in animal models and humans. In late stages of drug 
development, biomarkers can be used to make decisions in the evaluation of dose-response 
and optimal regimen for desired pharmacologic effect and safety, and some biomarkers can 
be used as a surrogate endpoint for efficacy and/or toxicity. Also, biomarkers can predict 
patients’ response to compound-enabling patient enrichment strategies by identifying 
certain patient populations that are more likely to respond to the drug therapy or to avoid 
specific adverse events. This shift toward “personalized medicine,” in which the patient 
receives a treatment based on his/her genetic makeup as well as medical profile, is helping 
the drug industry achieve the goal of quick and cost-effective research, especially in poorly 
served areas such as neurodegenerative disorders and cancer. 
Biomarker assays range from exploratory type of assays performed on a fit-for-purpose 
basis to rigorously validated assays when a biomarker is used as a surrogate end point, for 
patient selection, or for randomization into different arms. Validation of biomarker assays 
should be considered a continuous and evolving process. It is imperative that biomarker 
development be accelerated along with therapeutics. Assay validation is essential, but of 
equal or even greater importance is the monitoring of assay performance and level of 
quality during production. 
Despite all of the potential benefits of using biomarkers to advance pharmaceutical research 
and development, discrepant results can pose a threat to development programs by 
triggering false decisions.  
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
402 
This chapter will address the following topics; 
1. Biomarker classes and their potential utility in drug development. 
2. Pre-analytical, analytical, or post-analytical laboratory sources of errors.  
3. Biomarkers in personalized medicine, and ideal path for drug and companion 
diagnostic co-development. 
4. The major reasons behind discrepant results from biomarkers laboratories with real-life 
examples, their impact on the pharmaceutical industry, and how to mitigate them. 
2. Biomarker definition 
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or a pharmacologic response to a 
therapeutic intervention (Atkinson, 2001). According to the FDA’s definition, a biomarker is 
a measurable endpoint that can be used as an indicator of a particular disease or some other 
physiological state of an organism (FDA, 2011a). With these definitions, biomarkers include 
imaging (CT, MRI, PET, x-ray) or clinical laboratory testing which can span a whole range of 
laboratory testing including simple serum chemistries (e.g. blood glucose), 
immunochemistry, cell surface protein expression, drug metabolizing isoenzyme 
phenotype, blood pressure, psychometric testing, pain scales, microbial culture, pulmonary 
function tests, electrocardiogram, bone density, single gene mutations or global mutation 
scanning, gene amplification, targeted and global gene-expression, or protein and 
phosphoprotein signatures. 
3. Some historical background 
Medical practice in ancient times was performed mainly by physical examination and 
observation of the patient. However, testing of biological fluids for diagnostic and 
predictive purposes started around 6000 years ago with the analysis of human urine 
(Armstrong 2007). Prior to Hippocrates (460 – 370 BC), Babylonian, Egyptian and Far 
Eastern cultures were familiar with the diagnostic utility of urine. Urine assessments by 
Sumerian and Babylonian physicians were documented in as far back as 4000 BC, when they 
first discovered that something other than physical evidence of disease could be utilized to 
make a clinical decision. In those days, whenever a patient was diagnosed with a serious 
disease, they would ask him/her to breathe into a sheep’s nose. The animal would then be 
slaughtered and the liver removed and carefully inspected for evidence of disease. The 
resulting observation was to be used to predict the outcome of the patient’s case and its 
treatment. The Babylonians based this diagnostic art on their theory that the liver was the 
center of the human body’s organs and that the whole of human physiology occurred there, 
which aligns with our modern perception of the metabolic importance of hepatic cells.  
One of the earliest recorded diagnostic tests for hormones in body fluids was documented in 
the time of Ikhnaton and Cleopatra, when Egyptian pharaohs tested for pregnancy by 
adding a patient’s urine to a bag containing wheat and barley seeds. If the seeds germinated 
the woman was pregnant. If the barley seeds germinated first, it was an indication that the 
unborn infant was male, but if the wheat seeds germinated first then it indicated that the 
woman was carrying a female fetus. Testing of this pregnancy theory in 1963 showed 70% 
predictive value. Over the centuries, pregnancy testing became more sophisticated. In the early 
twentieth century scientists in several laboratories across Europe independently described the 
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presence of a substance that promotes ovary development and growth in rabbits and mice, 
and they recognized that the substance was a specific hormone, now known as human 
chorionic gonadotropin (hCG). In 1928 German scientists Aschheim and Zondek developed 
the first bioassay for hCG in urine by injecting a woman’s urine into an immature rat and 
looking for an estrous reaction; hyperemia of the ovaries and growth of the follicles.  
Another ancient diagnostic test was documented in Hindu cultures, utilizing the sweetness 
of urine and its ability to attract black ants to diagnose diabetes mellitus. (Winsten, 1969; 
Haber, 1988; Leavitt, 2006; Armstrong, 2007; Eknoyan, 2007; and NIH, 2011). Urine was 
once, and still is to a degree, regarded as a powerful fluid in many cultures. Towards the 
end of the 18th century, doctors with an interest in chemistry turned their attention to the 
scientific basis of urine analysis and to its use in practical medicine. To serve this interest, 
Boehringer Manheim launched the first urine dipstick in the mid-20th century. 
Over the last four decades, the importance of biomarkers in clinical trials and patient 
management has increased exponentially. The following graph (Figure 1) shows the number 
of publications listed on PubMed over the past 40 years for the keywords biomarker, clinical 
trial, and biomarkers & clinical trials. The number of hits increased 251-fold (from 325 to 
81545) for biomarker and 3045-fold (2 to 6089) for biomarker & clinical trial, versus 21-fold 
(4932 to 105533) for clinical trial from 1971/1972 to 2009/2010. These data indicate the 
significant growth in interest in biomarkers and their association with clinical trials over 
time. 
4. Brief biomarker laboratory regulatory aspects 
CLIA (Clinical Laboratory Improvement Act) certification and CAP (College of American 
Pathologists) accreditation have become a customary element of laboratory capability 
presentations. As a consequence of media coverage and public concern regarding false-
negative Pap smears in detecting cervical cancer, congressional hearings were held in 1976 
and again in 1988 on medical laboratory practices. Congress passed the Clinical Laboratory 
Improvement Amendments of 1988 (CLIA 1988) to ensure accuracy and reliability of 
laboratory testing. This legislation, for the first time, extended federal regulation to all 
laboratories (hospital, independent, and physician office laboratories, etc.) that perform 
microbiological, serological, chemical, hematological, immunohematological, 
immunological, toxicological, cytogenetical, exfoliative cytological, histological, pathological 
or other examinations performed on materials derived from the human body, for the 
purpose of diagnosis, prevention of disease, and treatment of patients. The Centers for 
Medicare & Medicaid Services (CMS) have primary responsibility under CLIA for 
regulating approximately 195,000 labs that are certified under CLIA. Since 1988, the CMS, 
along with the Food and Drug Administration (FDA) and the Centers for Disease Control 
and Prevention (CDC), has been working to improve the quality of laboratory testing 
through a variety of research, educational and enforcement activities. Of these quality 
enhancement measures, certified labs performing moderate and high complexity tests have 
been required, since 1994, to participate successfully in approved proficiency testing (PT) 
programs, which provide an external evaluation of the accuracy of each laboratory’s test 
results. These surveys may be conducted by the CLIA program, a State survey agency under 
contract with CMS, or private CMS-approved agencies such as Commission on Office 
Laboratory Accreditation (COLA), the Joint Commission on Accreditation of Healthcare 
Organizations (JCAHO), or CAP.  
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Fig. 1. Number of hits for “biomarker”, “clinical trial”, and “biomarker + clinical trial” in 
PubMed. 
CAP is the largest PT provider in the world, and is also the largest laboratory-accrediting 
agency in the United States. Through the PT program, the CAP provides individual 
laboratories with multiple specimens, usually three to five, for testing on three different 
occasions per year. The participants analyze the specimens and return results to the CAP for 
evaluation. Consequently, each participating laboratory receives a report of their performance 
along with a report summarizing the results of all participating laboratories in a peer group 
format. The CAP believes that by comparison to the most relevant instrument/reagent 
combinations, a laboratory’s performance is accurately assessed (www.CAP.org). The CAP 
automatically forwards results for analytes regulated for proficiency testing to the CMS for 
laboratories that are accredited by the US government under the CLIA. 
Of the tens of thousands of biomarker assays applied for different purposes in clinical trials, 
only 88 analytes (biomarkers) are regulated by CLIA-- 9 hematology, 17 general 
immunology, 1 diagnostic immunology, 5 immunohematology, 25 routine clinical 
chemistry, 7 endocrinology, 15 toxicology and therapeutic drug monitoring, and 9 
microbiology. For all other 'non-regulated' analytes, CLIA dictates that the laboratory must 
have a quality assurance plan that establishes the accuracy and reliability of the testing at 
least twice per year. Proficiency testing programs offer a wide array of products to 
conveniently assist laboratories in fulfilling this requirement (www.CAP.org). The CAP 
offers proficiency testing for more than 1,000 analytes. (CLIA, 1988; CMS, 2006; Paxton, 
2007; Howerton et al, 2010; Benneyan, 2011; and CAP, 2011). 
5. Utility of biomarkers in clinical trials 
High attrition rates are a critical issue in drug development, especially within oncology 
(Walker and Newell, 2009). The overall attrition rate for developing a drug was calculated to 
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be 10,000:1. From an average of 10,000 new chemical entities presented to pharmacology and 
safety testing, only about 10% (1000) would pass the criteria of activity and lack of toxic side 
effects. Of the 1,000 entities approved for clinical study, only 1% would show the combined 
safety and efficacy required by the clinic. Last but not least, out of the 10 NDA submissions 
to the FDA, only 10% of these (1 drug), on average, passes the review process (Network 
Science, 2011). This high attrition rate adds to the expensive and lengthy process of 
developing new medication, resulting in stagnation in the development of new compounds 
(Bowalekar, 2011).  
One of the options for the pharmaceutical industry to improve the high attrition rate during 
drug development is to move away from treat-and-see testing of new drugs in patients and 
focus on generating translational biomarkers early in the research process to enable more 
predictive evaluation of drug action in clinical trials (Gool et al, 2010). As a form of 
encouraging guidance, the FDA released a critical path initiative document in 2004, 
emphasizing the need for developing innovative trial designs. One of the innovations 
suggested was to use biomarkers to evaluate safety and effectiveness, predict effectiveness, 
provide informative links between mechanism of action and clinical effectiveness, connect 
animal and human studies, and serve as surrogate endpoints. New imaging technologies 
and emerging techniques of pharmacogenomics and proteomics show great promise in this 
respect, but much developmental work and standardization of the biological, statistical, and 
bioinformatics methods must occur before these techniques can be easily and widely 
applied (FDA, 2004).  
6. Classes of biomarkers in clinical trials 
Clinical laboratory measurements are an essential component of most drug studies to 
demonstrate safety and efficacy.  
6.1 Safety biomarkers 
Application of the most sensitive procedures to identify toxicity as early as possible in 
clinical development before engagement into expensive phase III trials is essential. Thus, at 
phases 1 and 2, careful selection of the correct tests should be mandatory, and the selection 
of those tests should be based on the compound profile and pre-clinical toxicology data 
(Craig, 2004). In addition to physical examination, vital signs, and electrocardiogram (ECG), 
constantly monitored safety lab biomarkers can act as common vital organ function tests 
applied across different therapeutic areas or as specialized testing applied to detect unique 
toxicities. Safety testing can be classified as follows: 
6.1.1 Liver safety tests 
The liver’s unique position between the gastrointestinal tract and the rest of the body, in 
addition to its vast capability to perform diverse functions essential for life, dictate its 
enormous role in maintaining metabolic homoeostasis of the body and turn it into the first 
resort for drugs and other toxicants. The most common tests applied in clinical trials are 
serum aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase 
(ALP), gamma-glutamyl transferase (GGT), and bilirubin. Changes observed in different 
liver tests depend on the significance of the liver’s involvement. ALT is located mainly in the 
cell cytosol but AST is located mainly in the mitochondria, which makes ALT quicker in 
release after acute hepatocellular injury. Also, ALT elevation lasts longer than AST’s, and it 
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is a more liver-specific enzyme for which serum elevation is rarely observed in conditions 
other than parenchymal liver damage. ALP and GGT are membrane-bound enzymes. ALP 
significantly increases in conditions that cause biliary obstruction but only moderately 
elevates in parenchymal cell damage. Although renal tissue has the highest content of GGT, 
the primary source of serum GGT is believed to be of hepatobilairy origin. Release of GGT 
into serum is caused by the toxic effect of alcohol or some drugs on the microsomal 
structures of hepatic cells. Bilirubin is a marker of the excretory liver functions, and both 
conjugated and unconjugated bilirubin increase in obstructive liver damage (Craig, 2004 and 
Balistreri and Rej, 1994). Albumin and prothrombin time can be used to assess changes in 
the synthetic functions of the liver but significant changes may only happen with chronic 
hepatocellular damage.  
According to the FDA’s guide, drug-induced liver injury (DILI) is predominantly 
hepatocellular damage that can be revealed by the rise in serum ALT or AST. The ability to 
cause some hepatocellular injury, however, is not a reliable predictor of a drug’s potential 
for severe DILI. Many drugs that cause transient rises in serum amino transaminases (AT) 
activity do not cause progressive or severe DILI, even if drug administration is continued. 
Severe DILI are induced by those drugs that can cause hepatocellular injury extensive 
enough to reduce the liver’s ability to clear bilirubin from the plasma or to synthesize 
prothrombin and other coagulation factors (FDA, 2009).  
6.1.2 Renal dafety tests 
In addition to its homeostatic and endocrine functions, the kidneys’ excretory function is 
essential for life, ridding the body of most of the present undesirable end products and 
toxicants. Blood urea nitrogen (BUN), serum creatinine, glomerular filtration rate (GFR), 
creatinine clearance, serum electrolytes (sodium, potassium, chloride, and bicarbonate), and 
complete urine analysis (color, pH, specific gravity, glucose, proteins, ketone bodies, and 
microscopic exam for blood, leukocytes, casts) are the traditional renal toxicity tests in 
clinical trials. Cystatin-c, β 2-microglobulin, uric acid, clusterin, N-acetyl-beta-d-
glucosaminidase, neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-d-
glucosaminidase (NAG), and kidney injury molecule-1 (KIM-1) have been used as 
nephrotoxic biomarkers and some of them were found to be superior to BUN and creatinine 
in detecting glomerular and tubular injury (Craig, 2004, Balistreri et, 1994, Tonomura et al, 
2010, Prozialeck et al, 2009, Guha et al, 2011, Alkhalaf et al, 2010, Vaidya et al, 2009, 
Dharnidharka et al, 2002, Dieterle et al, 2010, van Timmeren et al, 2007).  
6.1.3 Hematology safety biomarkers 
Bone marrow is a primary target for toxicity caused by many classes of drugs including 
cytotoxic compounds, and the effect can be reflected by changes in peripheral blood 
components. Complete blood count, one of the fundamental safety indices in drug 
development, includes total hemoglobin, hematocrit, red cell count, mean red cell volume, 
mean cell hemoglobin, red cell distribution width%, mean cell hemoglobin concentration, 
total white cell count, differential white cell count (Neutrophils, lymphocytes, basophils, 
esinophils, and monocytes), and platelets (Craig, 2004). 
6.1.4 Bone safety biomarkers 
Bone is a living connective tissue constantly undergoing a process of remodeling, which 
includes a degradation stage of bone resorption by the action of osteoclasts and a building 
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stage of formation mediated by the action of osteoblasts. Serum calcium and inorganic 
phosphates have been traditionally used as bone biomarkers in clinical trials.  
6.1.5 Basic metabolic dafety biomarkers 
Blood glucose, triglycerides (TG), total cholesterol, low density lipoprotein cholesterol (LDL-
c), and high density lipoprotein cholesterol (HDL-c).are commonly used within the safety 
biomarker panel but can be used as efficacy biomarkers too. 
6.1.6 Other specific safety biomarkers 
Other target organ or compound mechanism of action-driven biomarkers may include 
serum immunoglobulin levels, C-reactive protein (CRP), fibrinogen, thyroid stimulating 
hormone (TSH), thyroxine, testosterone, insulin, lactate dehydrogenase (LDH), creatine 
kinase (CK) and its isoenzymes, cardiac troponin (cTn), and methemoglobin can be used as 
markers for specific toxicities (Craig, 2004; Reagan, 2010 and Subramaniam et al, 2010).  
6.2 Efficacy biomarkers 
The purpose of efficacy testing differs fundamentally from safety monitoring in that 
biomarkers are being used to demonstrate a change in all, or at least a good proportion of 
treated subjects; in other words, the more positive the biomarker, the higher the efficacy of a 
drug. Efficacy biomarkers can be classified into the following groups: surrogate, predictive, 
pharmacodynamic (PD), and prognostic biomarkers. 
Figure (2) illustrates different classes of biomarkers; drug metabolizing enzyme, drug 
receptor, and intermediary pathway substrate polymorphisms as predictive of a drug 
response, an intermediary signal produced from the interaction of a drug with its receptor 
as a PD biomarker, and a surrogate biomarker to demonstrate the final drug action. The 
diagram shows that panels 1 and 4 have similar pharmacological pathway components, in 
terms of quality and quantity, but the magnitude of the endpoints’ action can be 
significantly affected by the rate of converting the inactive drug to an active one). Panels 2 
and 3, compared to Panel 1, show that two subjects may have the same efficiency of drug 
metabolizing enzymes but, due to mutations in the drug receptor or downstream 
intermediary protein substrate, the drug does not perform its intended final action. 
6.2.1 Surrogate biomarkers 
A surrogate endpoint is a laboratory or physical measurement used in clinical trials to 
indicate a drug’s response and can be used in place of a clinical endpoint (Lonn, 2001). A 
clinical endpoint is a characteristic or variable that reflects a patient’s health status, usually 
related to efficacy, and is usually acceptable as evidence of efficacy for regulatory purposes. 
A surrogate biomarker can be used to assess the benefit of or harm from a therapeutic agent, 
based on epidemiologic, 
Table (1) summarizes the basic biomaker safety panel recommended for each trial, which 
looks very similar to the basic standard-of-care lab profile:therapeutic, pathophysiologic, or 
other scientific evidence that links the biomarker to the clinical outcome (Woodcock, 2011). 
Surrogate biomarkers are hugely beneficial when substituted for clinically significant 
endpoints, also known as patient-oriented outcomes, which can be very time consuming 
and expensive to prove, for example, blood pressure (BP) for stroke or myocardial 
infarction. Other examples of surrogate biomarkers are cholesterol, LDL-c, triglycerides, 
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blood glucose, glycosylated hemoglobin (HbA1c), arterial plaque thickness, CD4 count or 
viral load for HIV response, HCV RNA viral load for HCV response, bacterial count, tumor 
size, and bone mineral density (Temple, 2009, Woodcock, 2011). Even if evidence for 
surrogacy is not enough, such types of biomarkers are useful in proving the concept for 
which a candidate drug is to be used, such as the inhibition of platelet aggregation by an 
antithrombotic agent (Temple, 2009).  
 
AST 
ALT 
ALP 
Bilirubin 
GGT 
Urea 
Creatinine 
Sodium 
Potassium 
Uric acid 
Glucose 
Cholesterol 
Total protein 
Albumin 
Calcium 
CRP 
Thyroxine 
TSH 
Complete blood count with platelets 
Complete urinalysis 
Table 1. Basic safety biomarker panel in clinical trials 
6.2.2 Predictive biomarkers 
Predictive biomarkers can stratify patient populations into responders and non-responders, 
predict whether or not a drug will have the intended effect, or forecast the extent to which a 
drug can be effective and/or toxic in different patient populations. The discovery of 
Cytochrome P450-2D6 (CYP2D6) polymorphism in 1977 (Mahgoub et al, 1977 and Tucker et 
al, 1977) opened the door for research on the impact of such metabolizing enzyme’s genetic 
variability on the efficacy and toxicity of drugs. However, 34 years after this discovery, only 
76 genetic and genomic biomarkers, mainly CYP2D6 followed by CYP2C19, are on FDA 
labels of 70 approved drugs, mainly for oncology and psychiatry followed by antiviral and 
cardiovascular drugs (Figure 3). Drug label information on genomic biomarkers can 
describe drug exposure and clinical response variability, risk for adverse events, genotype-
specific dosing, mechanisms of drug action, polymorphic drug target and disposition genes, 
and precautions- interactions, contraindications, patient counseling, nutritional 
management (FDA, 2011b). 
6.2.2.1 Predictive biomarkers in personalized medicine 
Completion of the human genome project about a decade ago enormously facilitated our 
understanding of human genetics and the associated biology, and it has become 
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increasingly clear that patients with different genetic makeup manifest diseases differently 
and respond to medication differently – in terms of both efficacy and safety. Also, there is a 
rapidly spreading notion that uncertainty about which patients might respond positively or 
negatively to a particular treatment regimen has significant consequences on patient health 
and attrition rate in drug discovery, that empirical drug development is unsustainable, and 
that biomarkers can provide guidance and help with these issues. In this respect, the 
personalization of medicine, via targeting the right population, offers the potential for 
mitigating the problem of universalizing therapy into a single, all-encompassing solution. If 
two populations with genetic and biological makeup similar to Panels 1 and 2 depicted 
above in Figure (2) use the same drug, Panel 1’s population would observe the desired effect 
while the population in Panel 2 would only be exposed to the side effects of the drug. The 
population depicted by Panel 4 will need to double the dose used for Panel 1 to get same 
value. Figure (4) illustrates the concept of predictive biomarkers and personalized medicine. 
In graph (A), the use of biomarker had no impact, while graph (B)’s biomarker-positive 
population responded significantly better to a target drug, as measured by survival rate, 
than the biomarker- negative population when treated with the same drug or the control 
arm (marker-positive or -negative) receiving the standard therapy. 
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Fig. 2. Illustration of surrogate, predictive, pharmacodynamic (PD) biomarkers. 
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6.2.2.2 Personalized medicine and companion diagnostics (CDx) 
Recent advances in cancer research have focused on drug candidates with specific molecular 
targets including mutated genes in cancer cells. To achieve the greatest benefit from such 
types of therapeutic agents, populations that are positive for the target should be identified 
and exclusively treated, and, in order to do that, an in-vitro diagnostic test (IVD) should be 
readily available. This IVD can be an existing test for a biomarker that is classified by the 
FDA as “known valid;” in other words, the biomarker is accepted by the scientific 
community at-large as a predictor of clinical outcomes, such as LDL-c, HbA1c, and 
CYP2C19. When a biomarker appears to have predictive value but is not yet replicated or 
widely accepted, it is classified by the FDA as “probable valid,” as in the cases of EGFR and 
KRAS mutations. These types of biomarkers can be used in targeted therapies to 
demonstrate the efficacy or toxicity of an agent during a drug’s clinical development, and 
then become “known valid” when treatment is approved (Frueh, 2006). This approach 
mandates co-development of an IVD with a drug- a companion diagnostic (CDx). 
 
 
Fig. 3. Biomarkers (A) listed on labels of FDA-approved drugs (B). 
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Fig. 4. Depiction of how a biomarker can predict response to a medication: the biomarker is 
predictive in Panel B but not in Panel A. 
Co-development can occur during any stage of drug development but, ideally, a biomarker 
should be integrated early in the drug’s development program so that trial data will support 
both drug and test approval. Clinical qualification of a biomarker should be prospective, but 
the retrospective path remains a possibility. Under any circumstances, the biomarker assay 
should be analytically validated before testing clinical samples. As shown by the following 
table (Table 2), only a few oncology drugs and IVD have been approved thus far 
(Datamonitor, 2011). Despite of the biological, analytical, clinical, regulatory, and project 
management hurdles, co-development of drugs and IVD appears to be the future in 
facilitating the personalized medicine approach. Figure (5) depicts the ideal path for drug-
IVD co-development. After the end of phase II and prior to initiation of pivotal phase III 
trial, in which the predictive biomarker will be used for patient randomization, both CDER 
(the Center for Drug Evaluation and Research; the branch of FDA responsible for drug 
approval) and CDRH (the Center for Devices and Radiological Health; the branch of FDA 
responsible for approval of medical devices), should approve the approach of co-
development. Figure (6) illustrates the process of qualifying a predictive biomarker in 
pivotal phase III. 
 
Drug  Indication Biomaker/CDx  
Imatinib (Gleevec)  CML 
BCR-ABL (PCR), c-KIT 
IHC  
Erlotinib (Tarceva) NSCLC, pancreatic  EGFR and KRAS mutation  
Gefitinib (Iressa) NSCLC EGFR and KRAS mutation 
Cetuximab (Erbitux) 
Colorectal cancer; head and 
neck cancer 
EGFR and KRAS mutation 
Panitumumab (Vectibix) Colorectal EGFR and KRAS mutation 
Trastuzumab (Herceptin)  
Breast cancer, 
gastrointestinal 
HER2 ISH, IHC, ELISA  
Table 2. Approved oncology drugs with diagnostic tests 
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Fig. 5. Ideal path for drug-IVD co-development. Blue; drug development, pink; IVD 
development. CDER; the Center for Drug Evaluation and Research (the branch of FDA 
responsible for drug approval), CDRH; the Center for Devices and Radiological Health (the 
branch of FDA responsible for approval of medical devices). 
 
 
Fig. 6. Qualification of a predictive biomarker in pivotal phase III trial 
6.2.3 Pharmacodynamic (PD) biomarkers 
These are the biomarkers which demonstrate that a drug hits its target and impacts its 
biochemical pathway. Such types of biomarkers are necessary to demonstrate proof of the 
drug’s mechanism of action (POM), i.e. markers of pharmacological response. This class 
constitutes the majority of biomarkers in early phases of drug discovery (preclinical, phase I, 
and, probably, phase II). In correlation with pahrmacokinetic (PK) measurements, this class 
of biomarkers can help to determine effective dose and dose schedule. The biomarker 
illustration in Figure (2) shows that detection of an intermediary signal can indicate that the 
drug hit its target and the magnitude of the signal can reflect the efficacy of the interaction. 
The contribution of biomarkers to the goals of 87 phase I oncology trials was analyzed to 
reveal that biomarkers supported the proposed mechanism of action in 39% of the trials, 
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contributed to dose selection for subsequent phase II studies in 13%, contributed to the 
selection of dosing schedule for phase II studies in 8%, and biomarkers were considered by the 
authors to be potentially useful for selecting a patient population in subsequent studies in 19% 
of the trials. These biomarkers were determined in serum (36.8% of total), tumor tissue (25.6%), 
peripheral blood mononuclear cells (22.7%), normal solid tissue (3.7%), and cerebrospinal fluid 
(0.2%), in addition to 10.9% by special in-vivo imaging. The non-imaging biomarkers included 
proteins, cytokines, and enzyme activity in serum, CSF, or tissue lysates, proteins by 
immunohistochemistry (IHC), and DNA and RNA gene expression (Goulart et al, 2007). 
6.2.4 Prognostic biomarkers 
Prognostic biomarkers can predict the risk or outcome of a disease in patient population 
without the involvement of therapy. For example, a population that tested positive for a 
given prognostic biomarker can survive longer or live better than another that tested 
negative. Figure (7) depicts the concept of a biomarker’s ability to predict overall survival in 
Panel A but not Panel B. In addition to its predictive power, prognostic biomarkers may 
help enrich a clinical trial by choosing people more likely to respond to treatment. Examples 
of prognostic biomarkers include prostatic specific antigen to predict survival in prostatic 
cancer patients (D’Amico et al, 2004 and Kelloff et al, 2004), Preoperative CA125 to predict 
metastatic disease in patients with uterine carcinoma (Gupta et al, 2011), and CRP as a risk 
factor in cardiovascular events (Ridker et al, 2008 and Abd et al, 2011), CRP to predict 
reduced overall and disease-free survival breast cancer ( Allin et al, 2011), and serum LDH 
to predict overall survival in metastatic brain tumors (Eigentler et al, 2011). The number of 
circulating tumor cells (CTC) was shown to predict overall and progression-free survival in 
patients with metastatic breast and ovarian cancers (FDA, 2005 and Poveda et al, 2011), and 
to predict the effect of treatment earlier than imaging (Nakamura et al, 2010). Also, HER2-
positive CTC was suggested as a prognostic value in metastatic breast cancer (Hayashi et al, 
2011). 
 
 
Fig. 7. Illustration of a prognostic biomarker. A biomarker can predict clinical outcome 
(survival) in Panel A but not in Panel B. 
7. Discrepant results and its major impact on clinical trials 
7.1 Types of laboratory errors 
Despite all of the potential benefits of using biomarkers to advance pharmaceutical research 
and development and to fully implement the concept of personalized medicine, discrepant 
results can be a threat to development programs by triggering false decisions. Many tools 
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and strategies have been adopted to enhance laboratory quality, including internal quality 
control (QC) procedures, external quality assessment programs, certification and 
accreditation, licensing of lab professionals, continuing education programs, and the 
regulation of lab services. Despite these quality measures, some imminent sources of error 
still require urgent intervention. 
Most errors affecting laboratory test results occur in the pre-analytical phase, where they 
account for more than 90% of the errors currently encountered within the entire diagnostic 
process, and the positive trends towards the reduction of laboratory errors over the past 
decade (predominantly those in the analytical phase) have hardly affected the pre-analytical 
phase (Lippi et al, 2006a; Lippi et al, 2006b and Lippi, 2009). Those variables often result in 
sub-optimal or poor specimen quality with the impact of producing incorrect results. 
Laboratory errors can be classified as pre-analytical, analytical, or post-analytical.  
7.1.1 Pre-analytical 
Pre-analytical errors occur between the test order and the analytical phase, and may affect 
sample integrity and its suitability for analysis. 
 
Patient preparation for the test 
- Nutritional status and diet influencing test results. 
- Physical activity prior to sampling. 
- Emotional distress prior to or during sampling. 
- Smoking. 
- Alcohol intake. 
- Menstruation and pregnancy in females. 
- Medications or suppliments that interfere with measured analytes. 
- Some clinical procedures and other diagnostic intervention. 
Phlebotomy-related 
- Wrong test ordered or incorrect timing of sampling. 
- Missing or wrong patient ID. 
- Posture of the patient during sampling. 
- Unsuitable tube or anticoagulant. 
- Incorrect source of blood (arterial versus venous).  
- Blood supply is not enough to collect adequate sample, e.g. collapsed vein. 
- Contamination from skin wipes. 
- Dilution of specimen from venous infusion or incorrect ratio of blood to liquid 
anticoagulant. 
- Hemoconcentration due to long application of tourniquet, especially at high pressure. 
- Improper mixing of anticoagulant which may produce partial clotting. 
- Hemolysis due to usage of small needle, vigorous mixing, or pneumatic tube systems 
with many curves. 
- Air bubbles. 
- Nonhomogenous blood sample due to partial clotting during collection from heel or 
finger sticks. 
- Wrong order of blood draw tubes. The recommended order is blood culture bottles, 
citrate, serum, heparin, EDTA, and then fluoride-containing tubes. 
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Sample processing, storage, and shipping-related 
- Inadequate coagulation time for serum separation. 
- Lag time between sampling and analysis. 
- Wrong centrifugation temperature, speed, or time. 
- Storage temperature or wrong freezer, e.g. automatic freeze-thaw. 
- Necrotic tissue/fluid or wrong tissue collected via fine needle biopsy. 
- Inappropriate acquisition and handling of fresh frozen tissue for RNA, proteins, or 
phosphoproteins analyses. 
- Inappropriate fixation and embedding of tissue biopsies into paraffin blocks. 
- Wrong thickness of tissue sections for histopathology, IHC, FISH, etc. 
- Unsuitable shipping conditions. 
Table (3) lists the most common pre-analytical variables that may impact biomarker results. 
These variables are the result of broad heterogeneity in several pre-analytical processes, 
mainly due to the lack of reliable guidelines (Lippi et al, 2006a, Lippi et al, 2006b, and Lippi, 
2009). Assurance of availability of appropriate lab instruments (mainly centrifuges and 
freezers) during clinical site qualification, along with clear, concise, illustrative lab manuals, 
well-trained phlebotomists, good techniques for tissue biopsy, and onsite training are 
essential tools in mitigating the pre-analytical lab errors. 
7.1.2 Post-analytical 
Post-analytical errors may occur after a sample has been processed and analyzed by an 
instrument, as listed in Table (4) below.  
 
- Improper documentation of test results, wrong manual transcription, or questionable 
interface between analyzing instrument and database. 
- Incorrect patient identification information entered at time of test. Patients’ results 
may be mixed with one another. 
- Failure to recognize and act on abnormal results, e.g. repetition of samples with 
unexpected results or panic values.  
Table 4. List of most common post-analytical variables 
Although uncommon, post-analytical errors can be very serious, especially when producing 
alarming values without verification, e.g. very low platelet count from a sample which was 
inappropriately collected or mixed. To mitigate this class of errors, the central lab has to 
implement an effective process for sample identification and acquisition, proper interface of 
testing device with the database, and a process for identification and repeat of analysis, and 
probably recollection, of samples with unexpected abnormal values especially those with 
panic results. A pharmaceutical company needs to take the proper measures to ensure error-
free post-analytical phase and reporting. 
7.1.3 Analytical 
With momentous efforts from lab professionals and in-vitro diagnostic partners, clinical 
laboratory errors due to analytical issues have been significantly reduced over time with the 
evolution of innovative technologies and the implementation of a number of quality control 
and quality assurance (QC&QA) check points, including internal (electronic) QC, liquid QC, 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
416 
calibration, delta checks, method comparison, and proficiency testing, among other 
measures. Figure (8) illustrates the two types of analytical errors: random (A) and systematic 
(B), where random error can affect a sample or a few samples within an analytical run while 
systematic error affects all samples analyzed after an error has occurred and until it is fixed.  
Each biomarker assay has a “default” imprecision, oscillation of values from the same 
sample, when measured multiple times, around the average of observations. Typically, a 
clinical lab considers an assay to be well-performing if results from a quality control sample 
are nicely distributed around the average and within “Average ± 2SD” as shown in Figure 
(8). Results scattered outside the 2SD limits in panel (A) denote random error, while panel 
(B) shows consistent drift or bias (systematic error). Random error is usually caused by the 
pipetting of wrong volumes, air bubbles, small clots, or inadequately mixed samples. 
Systematic error can affect a single analytical run or even just a part of a run, a few runs, or 
can have a longitudinal impact which may span the entire life of a testing device. Figure (8B) 
illustrates a short-term systematic error which may occur following inappropriate 
calibration of a device or an improperly qualified new lot of reagents. Figure (9) 
demonstrates a real example of the difference between results from splits of 43 samples 
analyzed for ALP on two different chemistry analyzers in two labs, where 9A shows that the 
actual values were remarkably higher in Lab B than Lab A, and 9B shows that the percent 
difference (% bias) of lab B from lab A ranged between 150 and 350% across different levels 
of ALP. 
 
 
Fig. 8. Illustration of random (A) and systematic error (B). 
 
 
Fig. 9. Systematic error in ALP between two analytical devices used at two different labs; (A) 
Actual ALP values from 43 split samples, and (B) is Bland-Altman plot for the percent of 
bias of Lab B from Lab A. 
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7.2 Lack of traceability as a major source of systematic errors 
The overall quality of clinical laboratory results can be compromised by the lack of 
traceability; absence of true method-to-method or platform-to-platform, or even between 
different reagent lots for an assay, standardization; or at least harmonization of test results. 
If assays or technologies are properly validated via proper method-to-method and lab-to-lab 
comparison, lack of traceability aspects, except reagent lot-to-lot variability, can be easily 
highlighted. Assay validation is always completed using the same lot or a few lots of 
reagent at best, which cannot detect low-performing lots afterwards. This is not only the 
problem of “sophisticated” biomarker assays, e.g. IHC, ISH, genotyping, etc., it also impacts 
supposedly well-standardized chemistry assays that have been used for decades as 
standard-of-care. 
In past publications (2009, 2011a, and 2011b), I emphasized the gravity of the problem. For 
one sample analyzed by more than 4,000 laboratories using different types of instruments 
and thromboplastin reagents, the INR (international normalized ratio of prothrombin time) 
values ranged between 2.9 and 7.6. When another sample was analyzed for activated partial 
thromboplastin time (aPTT), thrombin time (TT), and anti-FXa assay (Heparin test) in 
different labs employing different platforms and methodologies, the ratio of maximum to 
minimum reported results was up to 4-fold, 40-fold, and 50-fold, respectively. For yet 
another sample analyzed for ALP and LDH, the ratio was 4-fold. In other instances, percent 
difference between maximum and minimum HDL-c reported results from a sample 
analyzed on different platforms was up to 47%; and when another sample (with a target 
value of 152mg/dl as estimated by a standard procedure) was analyzed on different 
platforms for LDL-c, the reported results from different labs were between about 120 and 
202 mg/dl.  
Lack of traceability between different lab platforms or methodologies, even for well-
established technologies like chemistry or immunochemistry analyzers employed by central 
labs, is mainly due to unavailability of primary or secondary standards to calibrate devices 
or methodologies across different brands. Also, there is no “gold standard” device or 
methodology to use as a predicate even for well established lab analyzers. While greater 
automation and innovation has, in general, improved laboratory performance over the last 
decade, it is also a double-edged sword as, in the absence of a gold standard approach; this 
seems to contribute significant systematic bias between different devices and reagents. The 
way the FDA (2011) approves analytical devices or methodologies based on substantial 
equivalence to legally marketed devices (precedent devices) should be drastically revised. 
7.2.1 Impact of lack of traceability on clinical trials 
This long term systematic source of error is commonly overlooked and is often aggravated 
by the disconnect between clinical laboratory services on the one side, and clinicians, and 
drug developers on the other, and the misinterpretation of test results by following general 
clinical guidelines per test rather than using a reference range or set cut-off values for 
medical decisions for specific platforms/reagents. Considering the widely applicable INR 
therapeutic target range for Warfarin (2.0 to 3.0 units), a result from the sample mentioned 
above can be within the therapeutic target, indicate slight anticoagulation, or demonstrate 
dramatic anticoagulation which may need immediate medical intervention. The difference 
between maximum and minimum results from the anti-FXa example can be more than 23-
fold the unfractionated heparin (UFH) therapeutic range (0.35-0.70 U/ml). Following the 
National Cholesterol Education Program (NCEP) guidelines, a clinician may interpret the 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
418 
results from the LDL-c example as near optimal, borderline high, high, or very high and will 
treat his/her patient accordingly. 
The problem can impact decision making by pharmaceutical developers if they use absolute 
biomarker values to compare the outcomes of different studies on a drug’s efficacy and/or 
toxicity, or employing biomarkers to bridge between different drug candidates belonging to 
a particular class of compounds. Also, global clinical trials may be impacted where different 
specialty or safety biomarker labs are employed. It is not uncommon for different lab 
locations within a global organization (or even within one lab location) to use different 
platforms interchangeably to analyze samples from the same trial. 
A pharmaceutical development program may take as long as 10 years or more, thus 
switching biomarker vendors is likely, using multiple platforms or changing platforms by a 
lab is common, and employing different lots of reagents and calibrators is definite. Without 
paying close attention to these variables, results from different platforms, even from the 
same lab, may lead to erroneous go/no-go decisions and make compatibility of results from 
different studies almost impossible. Also, unless appropriately understood and interpreted, 
if such lab tests are used as an efficacy or toxicity biomarker, the drug may be 
inappropriately labeled. The inter-laboratory discrepancies in results could be even higher 
than those included in my articles, because data were gathered from “well-controlled” 
laboratories for theoretically standardized tests used to manage patients’ health and as 
surrogate biomarkers in clinical trials. Until global standardization or harmonization 
approaches are employed, the pharmaceutical industry needs to monitor biomarker data 
rigorously and understand these challenges for better interpretation of biomarker results. 
7.3 Impact of discrepant results on personalized medicine 
As explained earlier, companion diagnostics (CDx) are essential in enabling target 
therapeutic products to achieve their expected safety and efficacy. Therefore, the risk from 
failure of CDx is equal to the risk of wrongly using therapeutic products. It has been 
reported that BCR-ABL (leukemia biomarker and approved CDx) gene transcripts have 
been analyzed at over 150 hospitals and labs and results were non-comparable, where the 
number of transcripts reported from 6 CLIA-certified, reliable labs (two commercial and 4 
cancer institutions) varied by more than 2Logs. The introduction of common 
primers/reagents/calibrators, which was difficult to achieve, improved comparability 
(Jessup, 2011). 
In addition to the adverse effect of incorrect test results on patient management, the use of 
loosely validated assays may spoil a trial outcome and impose a wrong go/no-go decision, 
especially if the rate of target mutation is relatively small as shown by figure (10). For 
example, suppose the rate of a mutant gene is 20%, and the rate of response to a therapeutic 
agent is 70% and 10% in patients with mutant and wild type (WT) genes, respectively, such 
as tyrosine kinase inhibitors in mutant and WT EGFR (Mitsudomi and Yatabe, 2007), if the 
biomarker assay is 90% sensitive and 90% specific, which can be considered acceptable or 
good by some professionals, it would have two implications: 
1. In the clinical trial, the efficacy signal will be diluted, as instead of the two arms (WT 
and M) being cleanly separated (100% WT and 100% M in the corresponding arms) and 
the efficacy in the M arm clearly demonstrated, the signal in the M arm would be 
diluted by the carryover from the WT falsely identified as M. In this case, the average 
efficacy signal, or overall survival, will be less than the 100% M if identified by the 100% 
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specific assay. The signal in the WT arm would erroneously increase due to the 
carryover from M falsely identified as WT because of the 10% false negative, but as the 
majority is still WT, the impact is not as substantial as in the M arm. In this example, the 
average efficacy signal would be 0.52 and 0.12 in the M and WT arms instead of 0.70 
and 0.10 had the assay been 90% sensitive and 90% specific versus 100% and 100%. This 
means that the ratio of efficacy signal (in M arm to WT arm) would be reduced from 7.0 
to 4.4. Using the same model, such reduction in efficacy signal due to an assay’s low 
performance would change the efficacy signal in the target population of any given 
drug, such as Herceptin, where the average overall survival for patients with high 
levels of HER2 and control arm would change from 16 and 11.8 months (Roche, 2010) to 
14.7 and 11.9 months, respectively, decreasing the efficacy signal from 1.4 to 1.2. 
2. If the biomarker is used as a CDx to qualify a patient for treatment after drug approval, 
two out of the 20 M will not be given the drug (10%), and 8 out of 80 subjects with WT 
(10%) will be wrongly treated with the drug. 
8. Conclusion 
There is no doubt that biomarkers can play a vital role in drug development as tools to 
monitor drug toxicity, prove a compound mechanism of action, prove the concept for which 
a drug will be used, and predict efficacy and toxicity. Biomarker hypothesis-driven drug 
development and personalized medicine seem to be the future of drug industry. However, 
despite the enormous enhancement in biomarkers laboratories’ level of quality, some 
sources of errors still pose an imminent risk to drug development. Due to lack of 
standardization, even for well trusted safety biomarker assays, a major source of error is the 
discrepant results from different laboratories or even from the same lab employing different 
platforms or methodologies. This source of error is commonly overlooked and is often 
aggravated by the disconnect between clinical laboratory services on the one side, and 
clinical guidelines, clinicians, and drug developers on the other. Results from the same 
sample can vary substantially, even for trusted standardized tests from “well-controlled” 
laboratories, with consequent impact on drug developers’ decisions and patient 
management including personalized medicine approach.  
It may be expensive for pharmaceutical companies to operate and maintain in-house 
laboratories if assets are underutilized, due to a global shortage of good laboratory and QA 
professionals, a resulting difficulty in acquiring and maintaining laboratory certification and 
licensure, and rapidly evolving technologies. Therefore, outsourcing the lab services can be 
an attractive option. Using contract research organization or academic institution laboratory 
services may reduce overhead and operating costs and provide pharmaceutical companies 
with access to new technologies as needed. While greater automation has, in general, 
improved laboratory performance over the last decade, it is also a ‘double-edged sword’. 
The increase in automation combined with consolidation of instrument/reagent/calibration 
manufacturers has resulted in many suppliers oversimplifying technology and electronically 
locking-out laboratories from using competitors’ reagents or independent calibrators so as 
to increase sales and profits. Thus, laboratories have become deeply dependent on suppliers 
for their quality and are often forced to change methods, instruments, calibrators and 
reference ranges at the whim of suppliers. This has been further compounded by many 
laboratories attempting to cut costs by reducing experienced and educated laboratory 
professionals (doctoral level and even master’s level) who have the knowledge and 
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experience to maintain stable calibration and optimal accuracy and precision. In fact, some 
labs have gone further by reducing bench level personnel from 4-year degree certified 
medical technologists to 2-year associate degree laboratory technologists or lower. 
 
 
Mixed population (20M+80WT)
100% specific, 100% sensitive 90% specific, 90% sensitive
80WT 72 WT + 2 M 8WT + 18M20 M
If efficacy of drug is 70% in M and 10% in WT
0.10
Average final efficacy signal = Efficacy in each class identified by the test
0.70 0.12 0.52
 
Fig. 10. Impact of low sensitivity and sensitivity of a biomarker assay on the outcome of 
stratification of patients according to the status of a gene mutation.  
   
Averageefficacysignal in each arm
#of WT x efficacy of the drug in the WT + #of M xefficacyof thedrug in the M
=
Total numberof subjects in each arm
 
Regulatory and laboratory accrediting agencies need to pay more attention, find resources, 
and implement a road map to fix the major challenge in biomarker laboratory; lack of 
traceability between different technologies. Meanwhile, it remains the responsibility of drug 
developers to assure that a biomarkers lab has the right tools and skills to analyze samples 
from a clinical trial, the assay validation is at the level of the decision to be made, and that 
biomarker data are properly interpreted. 
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